| Plasma AR and abiraterone-resistant prostate cancer A Romanel, DG Tandefelt, V Conteduca, A Jayaram, N Casiraghi, ... Science translational medicine 7 (312), 312re10-312re10, 2015 | 454 | 2015 |
| Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus–related mixed cryoglobulinemia: a long-term study F Dammacco, FA Tucci, G Lauletta, P Gatti, V De Re, V Conteduca, ... Blood, The Journal of the American Society of Hematology 116 (3), 343-353, 2010 | 292 | 2010 |
| H. pylori infection and gastric cancer: state of the art V Conteduca, D Sansonno, G Lauletta, S Russi, G Ingravallo, ... International journal of oncology 42 (1), 5-18, 2013 | 275 | 2013 |
| Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution … V Conteduca, D Wetterskog, MTA Sharabiani, E Grande, ... Annals of Oncology 28 (7), 1508-1516, 2017 | 272 | 2017 |
| Clinical features of neuroendocrine prostate cancer V Conteduca, C Oromendia, KW Eng, R Bareja, M Sigouros, A Molina, ... European journal of cancer 121, 7-18, 2019 | 266 | 2019 |
| Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial D Sansonno, G Lauletta, S Russi, V Conteduca, L Sansonno, ... The oncologist 17 (3), 359-366, 2012 | 196 | 2012 |
| Precancerous colorectal lesions V Conteduca, D Sansonno, S Russi, F Dammacco International journal of oncology 43 (4), 973-984, 2013 | 165 | 2013 |
| Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone C Lolli, O Caffo, E Scarpi, M Aieta, V Conteduca, F Maines, E Bianchi, ... Frontiers in pharmacology 7, 376, 2016 | 160 | 2016 |
| Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer H Beltran, A Romanel, V Conteduca, N Casiraghi, M Sigouros, ... The Journal of clinical investigation 130 (4), 1653-1668, 2020 | 158 | 2020 |
| Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib C Lolli, U Basso, L Derosa, E Scarpi, T Sava, M Santoni, SJ Crabb, ... Oncotarget 7 (34), 54564, 2016 | 152 | 2016 |
| N-Myc–mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer A Berger, NJ Brady, R Bareja, B Robinson, V Conteduca, MA Augello, ... The Journal of clinical investigation 129 (9), 3924-3940, 2019 | 150 | 2019 |
| Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone S Salvi, V Casadio, V Conteduca, SL Burgio, C Menna, E Bianchi, L Rossi, ... British journal of cancer 112 (10), 1717-1724, 2015 | 143 | 2015 |
| Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer L Puca, K Gavyert, V Sailer, V Conteduca, E Dardenne, M Sigouros, ... Science translational medicine 11 (484), eaav0891, 2019 | 139 | 2019 |
| Cell-free DNA as a diagnostic marker for cancer: current insights S Salvi, G Gurioli, U De Giorgi, V Conteduca, G Tedaldi, D Calistri, ... Oncotargets and therapy, 6549-6559, 2016 | 130 | 2016 |
| Androgen receptor signaling pathways as a target for breast cancer treatment E Pietri, V Conteduca, D Andreis, I Massa, E Melegari, S Sarti, ... Endocr Relat Cancer 23 (10), R485-R498, 2016 | 126 | 2016 |
| Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies V Conteduca, M Aieta, D Amadori, U De Giorgi Critical reviews in oncology/hematology 92 (1), 11-24, 2014 | 109 | 2014 |
| Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone U De Giorgi, P Caroli, SL Burgio, C Menna, V Conteduca, E Bianchi, ... Oncotarget 5 (23), 12448, 2014 | 105 | 2014 |
| Barrett's esophagus and esophageal cancer: an overview V Conteduca, D Sansonno, G Ingravallo, S Marangi, S Russi, G Lauletta, ... International journal of oncology 41 (2), 414-424, 2012 | 100 | 2012 |
| Clinical outcomes of castration-resistant prostate cancer treatments administered as third or fourth line following failure of docetaxel and other second-line treatment … O Caffo, U De Giorgi, L Fratino, D Alesini, V Zagonel, G Facchini, ... European urology 68 (1), 147-153, 2015 | 98 | 2015 |
| Biological evolution of castration-resistant prostate cancer A Davies, V Conteduca, A Zoubeidi, H Beltran European Urology Focus 5 (2), 147-154, 2019 | 97 | 2019 |
